Completed
Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
What is being tested
Data Collection
Who is being recruted
Hematologic Diseases+13
+ Hemic and Lymphatic Diseases
+ Immune System Diseases
Over 18 Years
+31 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 1
Interventional
Study Start: February 2004
Summary
Principal SponsorSynta Pharmaceuticals Corp.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: February 1, 2004
Actual date on which the first participant was enrolled.The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
Official TitlePhase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
Principal SponsorSynta Pharmaceuticals Corp.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
42 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Hematologic DiseasesHemic and Lymphatic DiseasesImmune System DiseasesImmunoproliferative DisordersLeukemiaLymphatic DiseasesLymphomaLymphoproliferative DisordersNeoplasm MetastasisNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and SymptomsHematologic Neoplasms
Criteria
19 inclusion criteria required to participate
Male and female patients 18 years or older with one of the following malignancies:
Histologically or cytologically confirmed hematological malignancy (other than Acute Myeloid Leukemia and Myelodysplastic Syndrome) and if treatment is medically indicated, or,
Histologically-confirmed non-hematological malignancy that is metastatic or unresectable and for which no standard therapy is available.
Patients with CLL, PLL, CML, CTCL, ATL, and Non-Hodgkin's Lymphoma may be entered if they are refractory to or have relapsed following conventional chemotherapy regimens such as alkylating agents (e.g. chlorambucil and cyclophosphamide), anthracycline combinations [e.g. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)], and/or purine analogues (e.g. fludarabine monophosphate and 2-CDA) and are not currently being considered for re-treatment with conventional regimens
Show More Criteria
12 exclusion criteria prevent from participating
Women who are pregnant or lactating.
Patients who have had chemotherapy, radiotherapy (except palliative radiation delivered to < 20% of bone marrow), immunotherapy, or corticosteroids ( > 10 mg/day of prednisone or equivalent) within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
The use of nitrosoureas or mitomycin C within 6 weeks prior to study entry.
Patients with prior peripheral blood stem cell rescue or bone marrow transplantation.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 8 locations
Suspended
Wilshire Oncology Medical Group
Pomona, United StatesOpen Wilshire Oncology Medical Group in Google MapsSuspended
Baptist Cancer Institute
Jacksonville, United StatesSuspended
University of Chicago
Chicago, United StatesSuspended
Tufts New England Medical Center
Boston, United StatesCompleted8 Study Centers